SPTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Seaport Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$17.79−0.04 (-0.22%)
Close on Oct 19, 2026
- Market cap
- $626.85M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | Before market open | – | $-1.78 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Jun 8, 2026 | Before market open | – | $-10.34 | – |
Press releases
Announcements Seaport Therapeutics filed with the SEC
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Results of operations · EX-99.1 to Form 8-K
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Results of operations · EX-99.1 to Form 8-K